Top & Current
Fri, September 27, 2024
[ Fri, Sep 27th 2024
] - WOPRAI
Tue, August 13, 2024
[ Tue, Aug 13th 2024
] - WOPRAI
Mon, August 5, 2024
[ Mon, Aug 05th 2024
] - WOPRAI
Mon, July 8, 2024
[ Mon, Jul 08th 2024
] - WOPRAI
Wed, April 3, 2024
[ Wed, Apr 03rd 2024
] - WOPRAI
Mon, March 25, 2024
[ Mon, Mar 25th 2024
] - WOPRAI
Wed, November 15, 2023
[ Wed, Nov 15th 2023
] - WOPRAI
Fri, August 11, 2023
[ Fri, Aug 11th 2023
] - WOPRAI
Tue, July 11, 2023
[ Tue, Jul 11th 2023
] - WOPRAI
Tue, June 27, 2023
[ Tue, Jun 27th 2023
] - WOPRAI
Fri, June 23, 2023
[ Fri, Jun 23rd 2023
] - WOPRAI
Tue, July 12, 2022
[ Tue, Jul 12th 2022
] - WOPRAI
Wed, March 9, 2022
[ Wed, Mar 09th 2022
] - WOPRAI
Thu, October 21, 2021
[ Thu, Oct 21st 2021
] - WOPRAI
Srikripa Devarakonda Upgraded (BMEA) to Strong Buy and Held Target at $54 on, Sep 27th, 2024
Srikripa Devarakonda of Truist Securities, Upgraded "Biomea Fusion, Inc." (BMEA) to Strong Buy and Held Target at $54 on, Sep 27th, 2024.
Srikripa has made no other calls on BMEA in the last 4 months.
There are 6 other peers that have a rating on BMEA. Out of the 6 peers that are also analyzing BMEA, 1 agrees with Srikripa's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Robyn Karnauskas of "Truist Securities" Downgraded from Strong Buy to Hold on, Tuesday, June 11th, 2024
These are the ratings of the 5 analyists that currently disagree with Srikripa
- Tony Butler of "Rodman & Renshaw" Upgraded from Hold to Strong Buy and Held Target at $18 on, Thursday, September 26th, 2024
- Naureen Quibria of "Capital One" Initiated at Buy and Held Target at $25 on, Thursday, August 29th, 2024
- Yigal Nochomovitz of "Citigroup" Maintained at Strong Buy with Decreased Target to $22 on, Tuesday, August 27th, 2024
- Joseph Catanzaro of "Piper Sandler" Maintained at Buy with Decreased Target to $10 on, Friday, June 7th, 2024
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Decreased Target to $60 on, Thursday, May 30th, 2024